Case Report: Conversion therapy for initially unresectable intrahepatic cholangiocarcinoma
Frontiers in Oncology · 23.06.2026 · 16
DOI: 10.3389/fonc.2026.1722347 ↗Kurz gefasst
Fallbericht in der Zeitschrift Frontiers in Oncology, online erschienen am 23.06.2026. Verfasst von Ying-Ao Liu und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Surgery, Xuanwu Hospital, Capital Medical University, Beijing, China. Die Arbeit nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Intrahepatic Cholangiocarcinoma (ICC) is a highly malignant tumor originating from the intrahepatic biliary epithelium, characterized by strong invasiveness and poor prognosis. For patients with unresectable advanced ICC, the current first-line standard treatment is the gemcitabine plus cisplatin regimen, but its efficacy is limited. In recent years, with the exploration of immunotherapy, targeted therapy, and various combination treatment modalities, new directions have been provided for the treatment of advanced ICC. Case presentation This article reports a case of a patient with initially unresectable ICC who underwent conversion therapy with percutaneous portal vein embolization (PVE) combined with surufatinib (a multi-kinase inhibitor targeting VEGFR, FGFR, and CSF-1R), sintilimab (a PD-1 inhibitor), and the FOLFOX regimen (leucovorin, fluorouracil, and oxaliplatin). This approach successfully enabled radical liver resection and resulted in long-term disease-free survival. The patient was a 71-year-old male diagnosed via enhanced CT and MRI with a large liver mass accompanied by portal vein tumor thrombus. Pathological confirmation by needle biopsy confirmed intrahepatic cholangiocarcinoma. Due to extensive tumor invasion and insufficient future liver remnant (FLR), the tumor was assessed as unresectable. The treatment team adopted a multimodal conversion strategy: first performing PVE to promote compensatory hyperplasia of the FLR; subsequently administering 4 cycles of surufatinib, sintilimab combined with FOLFOX chemotherapy. Post-treatment imaging evaluation showed significant tumor shrinkage, along with an increase in FLR volume, meeting the criteria for safe radical surgery. Two weeks after stopping medication, the patient underwent right hemihepatectomy, caudate lobe resection, cholecystectomy, hepatoduodenal lymph node dissection and inferior vena cava repair. The patient recovered well postoperatively. At the last follow-up, he had achieved 28 months of disease-free survival with no evidence of local recurrence or distant metastasis.
Conclusion
For initially unresectable ICC, conversion therapy with PVE combined with surufatinib, sintilimab, and the FOLFOX regimen can significantly increase the tumor resection rate and achieve long-term survival. This strategy combines high anti-tumor efficacy with clinical feasibility, providing a new approach for the conversion therapy of advanced ICC. Further larger sample studies are needed in the future to verify its efficacy and safety.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of General Surgery, Xuanwu Hospital, Capital Medical University, Beijing, China.
- Department of General Surgery, Peking Union Medical College Hospital, Beijing, China.
- Department of Pathology, Xuanwu Hospital, Capital Medical University, Beijing, China.
Zitieren
APA
Liu, Y. A., Huang, Q., Gao, X., Gao, W., Hu, Z., Wang, F., Qu, Y., & Zheng, Y. (2026). Case Report: Conversion therapy for initially unresectable intrahepatic cholangiocarcinoma. Frontiers in Oncology, 16. https://doi.org/10.3389/fonc.2026.1722347
Vancouver
Liu YA, Huang Q, Gao X, Gao W, Hu Z, Wang F, et al. Case Report: Conversion therapy for initially unresectable intrahepatic cholangiocarcinoma. Frontiers in Oncology. 2026;16. doi:10.3389/fonc.2026.1722347
BibTeX
@article{Liu2026,
author = {Liu, Ying-Ao and Huang, Qi and Gao, Xiang and Gao, Wei and Hu, Zeliang and Wang, Fangzhou and Qu, Yuanxu and Zheng, Yamin},
title = {Case Report: Conversion therapy for initially unresectable intrahepatic cholangiocarcinoma},
journal = {Frontiers in Oncology},
year = {2026},
volume = {16},
doi = {10.3389/fonc.2026.1722347}
}
EUVIMED